Authors: Michael S Broder Maureen P Neary Eunice Chang Dasha Cherepanov William H Ludlam
Publish Date: 2014/05/07
Volume: 18, Issue: 3, Pages: 283-289
Abstract
MarketScan Commercial database 2007–2010 age 65 years was used CS patients were defined with ≥2 claims of CS diagnosis while CD patients were defined with CS plus a benign pituitary adenoma diagnosis or hypophysectomy in the same calendar year Annual incidence was calculated by dividing the number of CS or CD cases by the total number of members with the same enrollment requirement during the calendar yearsCS incidence rates per million personyears were 486 in 2009 and 395 in 2010 The lowest rates of CS were in ≤17yearolds and highest rates were in 35 to 44yearolds CD incidence rates were 76 in 2009 and 62 in 2010 The lowest rates of CD were in ≤17yearolds and highest rates were in 18 to 24yearolds The rates varied by sex 23–27 in males 98–121 in females In females lowest rates ranged 25–40 in ≤17yearolds and highest 167–272 in 18–24 year olds In males there were too few cases to report estimates by ageIn the first large USbased study the annual incidence of CS in individuals 65 years old was nearly 49 cases per million substantially higher than previous estimates which were based primarily on European data Using similar methods we estimated the incidence of CD at nearly 8 cases per million US population These estimates if confirmed in other epidemiologic databases represent a new data reference in these rare conditionsThis study was funded by Novartis Pharmaceuticals Corporation Maureen P Neary and William H Ludlam are employees of Novartis Pharmaceuticals Corporation Michael S Broder Eunice Chang and Dasha Cherepanov are employees of Partnership for Health Analytic Research LLC a health services research company paid by Novartis to conduct this research
Keywords: